Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.8700
-0.0576 (-6.21%)
At close: Jun 27, 2025, 4:00 PM
0.8610
-0.0090 (-1.03%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Biodexa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
2.51M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
| Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BDRX News
- 22 hours ago - Results of Annual General Meeting - GlobeNewsWire
- 2 days ago - Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 4 days ago - Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 10 days ago - Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study - Accesswire
- 16 days ago - Result of General Meeting - GlobeNewsWire
- 23 days ago - Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - GlobeNewsWire
- 4 weeks ago - Shareholder Update - GlobeNewsWire
- 5 weeks ago - Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting - GlobeNewsWire